All In Biotech

Drug Trial Radar · NCT06873763

Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer

A Single-arm, Phase Ib/2 Study of Nelmastobart in Combination With Trifluridine/Tipiracil and Bevacizumab in Metastatic/Recurrent Colorectal Cancer Patients With Resistance or Intolerance to Oxaliplatin and Irinotecan-based Chemotherapy

Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Jun 9, 2025

Primary completion

Dec 2025

Study completion Mar 2027

Sponsor

Lead sponsor
STCube, Inc.Industry
Sponsor type
Industry
First posted
Mar 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this multi-center, single-group, open-label Phase Ib/II study is to evaluate the safety, pharmacokinetics, and efficacy of nelmastobart in combination with trifluridine/tipiracil and bevacizumab in metastatic or recurrent colorectal cancer patients with resistance or intolerance to oxaliplatin- and irinotecan-based chemotherapy, and to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and the efficacy and safety of the combination therapy in BTN1A1-positive patients.

Conditions

  • Metastatic Colorectal Cancer (CRC)
  • Recurrent Colorectal Cancer

Interventions

  • Nelmastobart 800 mg+Trifluridine/Tipiracil+ BevacizumabDrug

    Trifluridine/tipiracil is dose-deescalated from 35 mg/m² to 30 mg/m² and 25 mg/m² to determine the RP2D, in combination with fixed doses of Nelmastobart and Bevacizumab, in patients with metastatic colorectal cancer who are refractory or intolerant to prior oxaliplatin- and irinotecan-based chemotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of DLTTime frame: up to 6 months
  2. RP2D(Recommended Phase 2 Dose)Time frame: up to 2 years
  3. MTD(Maximum Tolerated Dose)Time frame: up to 2 years
  4. Progression Free Survival (PFS) rateTime frame: up to 2 years

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Korea University Anam Hospital

    Seoul, South Korea · Recruiting

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea · Not yet recruiting

  • Seoul National University Hospital

    Seoul, KR, South Korea · Not yet recruiting

  • Severance Hospital

    Seoul, KR, South Korea · Not yet recruiting

  • Asan Medical Center

    Seoul, KR, South Korea · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.